New anticoagulants

Seminars in Thrombosis and Hemostasis

Volumn 32, Issue 8, 2006, Pages 793-802

  Agnelli, Giancarlo ^a   Becattini, Cecilia ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Anticoagulant therapy; Anticoagulants; Antithrombotic therapy; Direct thrombin inhibitors; Factor Xa inhibitors

Indexed keywords

ANTICOAGULANT AGENT; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 7A; DABIGATRAN; DALTEPARIN; DERMATAN SULFATE; DROTRECOGIN; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; FONDAPARINUX; HEPARIN; HIRULOG; IDRAPARINUX; PEPTIDE NAPC2 FX COMPLEX; POLYPEPTIDE; RAZAXABAN; RECOMBINANT HIRUDIN; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; THROMBIN INHIBITOR; XIMELAGATRAN;

ANTICOAGULATION; BLEEDING; BLOOD CLOTTING; CLINICAL TRIAL; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DRUG APPROVAL; DRUG MECHANISM; DRUG SAFETY; DRUG USE; HUMAN; META ANALYSIS; MOLECULAR MODEL; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; THROMBOEMBOLISM; THROMBOSIS PREVENTION;

ANTICOAGULANTS; BLOOD COAGULATION; CLINICAL TRIALS; DRUGS, INVESTIGATIONAL; HEMORRHAGE; HUMANS; THROMBOEMBOLISM;

EID: 33845616746     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-955462     Document Type: Review

References (76)

1. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin. Chest 2004;126:S188-S203
2. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists. Chest 2004;126:204S-233S
3. Weitz JI, Hirsh J, Samama MM. New anticoagulant drugs. Chest 2004;126:265S-286S
4. Furie B, Furie BC. Molecular and cellular biology of blood coagulation. N Engl J Med 1992;326:800-806
5. Mann KG, Butenas S, Brummel K. The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol 2003;23:17-25
6. Abraham E, Reinhart K, Svoboda P, et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 2001;29:2081-2089
7. Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003;290:238-247
8. Taylor FB Jr. Role of tissue factor and factor Vila in the coagulant and inflammatory response to LD100 Escherichia coli in the baboon. Haemostasis 1996;26:83-91
9. Jang Y, Guzman LA, Lincoff AM, et al. Influence of blockade at specific levels of the coagulant cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation 1995;92:3041-3050
10. Lincoff AM. First clinical investigation of a tissue-factor inhibitor administered during percutaneous coronary revascularization: a randomized, double-blinded, dose-escalation trial-assessing safety and efficacy of FFR-FVIIa in percutaneous transluminal coronary angioplasty (ASIS) trial. J Am Coll Cardiol 2000;36:312 (abst)
11. Cappello M, Vlasuk GP, Bergum PW, Huang S, Hotez PJ. Ancylostoma caninum anticoagulant peptide: a hookworm-derived inhibitor of human coagulation factor Xa. Proc Natl Acad Sci USA 1995;92:6152-6156
12. Stassen P, Bergum PW, Gansemans Y, et al. Anticoagulant repertoire of the hookworm Ancylostoma caninum. Proc Natl Acad Sci USA 1996;93:2149-2154
13. Lee A, Agnelli G, Bller H, et al. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of post-operative venous thromboembolism in patients undergoing total knee replacement. Circulation 2001;104:74-78
14. Rezaie AR. Prothrombin protects factor Xa in the prothrombinase complex from inhibition by the heparin-antithrombin complex. Blood 2001;97:2308-2313
15. Brufatto N, Nesheim ME. The use of prothrombin (S525C) labeled with fluorescein to directly study the inhibition of prothrombinase by antithrombin during prothrombin activation. J Biol Chem 2001;276:17663-17671
16. Boneu B, Necciari J, Cariou R, et al. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/ORG31S40) with high affinity to antithrombin III in man. Thromb Haemost 1995;74:1468-1473
17. Eriksson BI, Bauer KA, Lassen MR, Turpie AG. Steering Committee of the Pentasaccharide in hip fracture. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001;345:1298-1304
18. Lassen MR, Bauer KA, Eriksson BI, Turpie AG. European Pentasaccharide elective surgery study (EPHESUS) Steering Committee. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002;359:1715-1720
19. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. PENTATHLON 2000 Steering Committee. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002;359:1721-1726
20. Bauer KA, Eriksson BI, Lassen MR, Turpie AG. Steering Committee of the Pentasaccharide in major knee surgery study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001;345:1305-1310
21. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux versus enoxaparin for prevention of venous thromboembolism in major orthopaedic surgery. A meta-analysis of 4 randomized, double blind studies. Arch Intern Med 2002;162:1833-1840
22. Büller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease. Chest 2004;126:S401-S428
23. Eriksson BI, Lassen MR. PENTasaccharide in Hip-FRAture Surgery Plus Investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo controlled, double-blind study. Arch Intern Med 2003;163:1337-1342
24. Agnelli G, Bergqvist D, Cohen A, Callus A, Gent M. A randomized double-blind study to compare the efficacy and safety of fondaparinux with dalteparin in the prevention of venous thromboembolism after high-risk abdominal surgery: the Pegasus Study. J Thromb Haemost 2003;1(suppl):OC006 (abst)
25. Cohen AT, Gallus AS, Lassen MR, et al. Fondaparinux vs. placebo for the prevention of venous thromboembolism in acutely ill medical patients (artemis). J Thromb Haemost 2003;1(suppl):2046 (abst)
26. Buller HR, Davidson BL, Décousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004;140:867-873
27. The MATISSE Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003;349:1695-1702
28. Coussement PK, Bassand JP, Convens C, et al. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction: the PENTALYSE study. Eur Heart J 2001;22:1716-1724
29. Ferguson JJ. Meeting highlights: American Heart Association scientific sessions 2001. Circulation 2002;105:e37-e41
30. Herbert JM, Herault JP, Bernat A, et al. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 1998;91:4197-4205
31. Persist Investigators. A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis: a phase II evaluation. J Thromb Haemost 2004;2:47-53
32. Lassen MR, Davidson BL, Gallus A, et al. A phase II, randomized, double blind, five-arm, parallel-group, dose-response study of a new oral directly-acting factor Xa inhibitor, razaxaban, for prevention of deep vein thrombosis in knee-replacement surgery - on behalf of the Razaxaban Investigators. Blood 2003;102(suppl):11 (abst 41)
33. Esmon CT, Ding W, Yasuhiro K, et al. The protein C pathway: new insights. Thromb Haemost 1997;78:70-74
34. Bernard GR, Vincent JL, Laterre PF, et al. Efficaq and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709
35. Moll S, Lindley C, Pescatore S, et al. Phase 1 study of a novel recombinant human soluble thrombomodulin ART-123. J Thromb Haemost 2004;2:1745-1751
36. Kearon C, Comp P, Douketis J, et al. A dose-response study of a recombinant soluble thrombomodulin (ART-123) in the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2005;3:962-968
37. Weitz JI, Bller HR. Direct thrombin inhibitors in acute coronary syndromes: present and future. Circulation 2002;105:1004-1011
38. Weitz JI, Crowther M. Direct thrombin inhibitors. Thromb Res 2002;106:V275-V284
39. Agnelli G, Cosmi B, Di Filippo P, et al. A randomised, double-blind, placebo-controlled trial of dermatan sulphate for prevention of deep vein thrombosis in hip fracture. Thromb Haemost 1992;67:203-208
40. Taliani MR, Agnelli G, Nenci GG, Gianese F. Dermatan suphate in patients with heparin induced thrombocytopenia. Br J Haematol 1999;104:87-89
41. Wallis RB. Hirudins: from leeches to man. Semin Thromb Hemost 1996;22:185-196
42. Toschi V, Lettino M, Gallo R, Badimon JJ, Chesebro JH. Biochemistry and biology of hirudin. Coron Artery Dis 1996;7:420-428
43. Lefevre G, Duval M, Gauron S, et al. Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin. Clin Pharmacol Ther 1997;62:50-59
44. Eriksson BI, Ekman S, Lindbratt S, et al. Prevention of thromboembolism with use of recombinant hirudin: results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement. J Bone Joint Surg Am 1997;79:326-333
45. Eriksson BI, Wille-Jørgensen P, Kalebo P, et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997;337:1329-1335
46. Organization to Assess Strategies for Ischemic Syndromes Investigators. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: a pilot study: Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. Circulation 1997;96:769-777
47. Organization to Assess Strategies for Ischemic Syndromes Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularization procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial Organization to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Lancet 1999;353:429-438
48. Antman EM, and the TIMI 9A Investigators. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Circulation 1994;90:1624-1630
49. Neuhaus KL, von Essen R, Tebbe U, et al. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study: a study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK). Circulation 1994;90:1638-1642
50. The GUSTO IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes: the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa investigators. Circulation 1994;90:1631-1637
51. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction: the GUSTO Investigators. N Engl J Med 1993;329:673-682
52. The GUSTO IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes: the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) lib Investigators. N Engl J Med 1996;335:775-782
53. Metz BK, White HD, Granger CB, et al. Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial: Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators. J Am Coll Cardiol 1998;31:1493-1498
54. Serruys PW, Herrman JP, Simon R, et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty: Helvetica Investigators. N Engl J Med 1995;333:757-763
55. Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JW II. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990;29:7095-7101
56. Ginsberg JS, Michael T, Nurmohamed MT, et al. Use of hirulog in the prevention of venous thrombosis after major hip or knee surgery. Circulation 1994;90:2385-2389
57. Hursting MJ, Alford KL, Becker JC, et al. Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor. Semin Thromb Hemost 1997;23:503-516
58. Banner DW, Hadvary P. Inhibitor binding to thrombin: x-ray crystallographic studies. Adv Exp Med Biol 1993;340:27-33
59. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000;20:318-329
60. Gustafsson D, Nystrom JE, Carlsson S, et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/ 95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 2001;101:171-181
61. Eriksson BI, Bergqvist D, Kalebo P, et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002;360:1441-1447
62. Eriksson BI, Agnelli G, Cohen AT, et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee joint replacement. Thromb Haemost 2003;89:288-296
63. Eriksson BI, Agnelli G, Cohen AT, et al. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement. The EXPRESS study. J Thromb Haemost 2003;1:2490-2496
64. Francis CW, Davidson BL, Berkowitz SD, et al. Ximelagatran versus warfarin for the prevention of VTE after total knee arthroplasty. Ann Intern Med 2002;137:648-655
65. Francis CW, Berkowitz SD, Comp PC, et al. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003;349:1703-1712
66. Colwell CW, Berkowitz SD, Davidson BL, et al. Randomized, double blind comparison of Ximelagatran, an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee replacement (TKR) EXULT-b. Blood 2003;102:11 (abst 39)
67. Eriksson H, Wahlander K, Gustafsson D, Welin LT, Frison L, Schulman S. Thrive Investigators. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemost 2003;1:41-47
68. Fiessinger JN, Huisman MV, Davidson BL. the THRIVE Investigators. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis a randomized trial. JAMA 2005;293:681-689
69. Schulman S, Wahlander K, Lundstrom T, Clason SB, Eriksson H, for the THRIVE III Investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003;349:1713-1721
70. Petersen P, Grind M, Adler J, et al. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding tolerability, and safety study. J Am Coll Cardiol 2003;41:1445-1451
71. Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): a randomized trial. Lancet 2003;362:1691-1698
72. SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. A randomized trial. JAMA 2005;293:690-698
73. Halperin JL, for the Executive Steering Committee, SPORTIF III and V Study Investigators. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J 2003;146:431-438
74. Wallentin L, Wilcox RG, Weaver WD, et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 2003;362:789-797
75. Eriksson BI, Dahl OE, Ahnfelt I, et al. Dose escalating safety of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: Bistro I. J Thromb Haemost 2004;2:1573-1580
76. Eriksson BI, Dahl OE, Büller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for the prevention of thromboembolic events following total hip or knee replacement: the Bistro II randomized trial. J Thromb Haemost 2005;3:103-111